The global multiple sclerosis diagnostics market is projected to experience significant growth, reaching USD 12.88 billion by 2035, driven by technological advancements in neuroimaging and a growing emphasis on early diagnosis.
In 2025, the market size is estimated at USD 5.70 billion, with an anticipated increase to USD 6.20 billion in 2026. The compound annual growth rate (CAGR) from 2026 to 2035 is expected to be 8.80%. North America currently leads the market, holding a 40% share, while the Asia-Pacific region is forecasted to grow the fastest at a CAGR of 13.2% during the same period. Magnetic resonance imaging (MRI) remains the dominant diagnostic method, accounting for 42% of the market, followed by blood-based biomarker testing, which is expected to grow rapidly.
Technological advancements, particularly in MRI techniques, are key drivers of this market expansion, enabling earlier and more accurate diagnoses. The integration of artificial intelligence is also transforming the landscape by streamlining the detection process, allowing for quicker analysis and the identification of subtle biomarkers. This shift towards automation and precision is crucial for improving patient outcomes, as early diagnosis can lead to more effective treatment strategies.
However, the market faces challenges, such as a shortage of skilled healthcare professionals, which can delay diagnoses and limit access to care. Nonetheless, the emergence of predictive diagnostic software presents a significant opportunity, facilitating proactive approaches to patient management and potentially enhancing the effectiveness of therapies. As the market evolves, the focus on less invasive testing methods and advanced biomarkers will likely reshape the diagnostics landscape for multiple sclerosis.